Malvern Releases New Guidance on the Use of Automated Imaging for Agglomerate Detection
Malvern Instruments has released new guidance on using automated image analysis to detect and quantify agglomerates. The ability of uncontrolled agglomeration to substantially impact the performance and value of powder products makes efficient agglomerate detection vital across a number of industries. ‘Identification of agglomerates using automated image analysis’ presents practical strategies for efficiently and robustly differentiating agglomerates from primary particles, to support product development, QC and process troubleshooting. To view the application note, go to http://www.malvern.com/identifying-agglomerates.
Agglomerates are formed through the adhesion or cohesion of smaller primary particles. They can have serious implications for product performance, value and, in the case of pharmaceutical products, safety. Any tendency towards agglomeration must therefore be thoroughly investigated during product development, controlled during manufacture and checked in final product QC.
Automated imaging is a fast and efficient technique for studying the morphological characteristics of particulate materials. The new guidance shows how the combination of size and shape data can be used to securely classify particles as agglomerates, enabling the amount of agglomerated material present in a blend to be quantified. In particular, shape parameters such as particle convexity and circularity are shown to be important in differentiating primary particles and agglomerates.
Malvern’s Sysmex FPIA 3000 and Morphologi G3 image analysis-based particle characterisation systems employ advanced optics to record and analyze images of thousands of particles within suspensions, emulsions and dry powders in a matter of minutes. The Morphologi G3-ID extends the capabilities of image analysis by applying the technique of Morphologically Directed Raman Spectroscopy to enable the chemical identification of multi-component agglomerates that cannot be reliably classified on the basis of size and shape alone. Together, these automated imaging systems provide an efficient solution for robust agglomeration detection.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance